Brought to you by 
Genzyme and Isis enter $1.2bn CV collaboration
Jan 2008
Executive Summary
Genzyme and antisense drug developer Isis have agreed to partner for the development of Isis' mipomersen (formerly ISIS 301012), a Phase III injectable that lowers lipid levels in patients with familial hypercholesterolemia (FH).
Deal Industry
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- R+D and Marketing-Licensing
- Includes Royalty or Profit Split Information
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genzyme and Isis enter $1.2bn CV collaboration
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice